Chemoradiation for Esophageal Cancer

Thoracic Surgery Clinics

Volumn 23, Issue 4, 2013, Pages 551-558

  Blum, Mariela A ^a   Taketa, Takashi ^a   Sudo, Kazuki ^a   Wadhwa, Roopma ^a   Skinner, Heath D ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Definitive chemoradiation; Esophageal carcinoma; Multimodality therapy; Radiotherapy

Indexed keywords

BLEOMYCIN; CISPLATIN; FLUOROPYRIMIDINE; FLUOROURACIL; METHOTREXATE; MITOMYCIN;

ADENOCARCINOMA; ANUS CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); ESOPHAGUS CANCER; ESOPHAGUS RESECTION; GLUCOSE INTAKE; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; METASTASIS; MINIMAL RESIDUAL DISEASE; MOLECULAR BIOLOGY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT RESPONSE;

DEFINITIVE CHEMORADIATION; ESOPHAGEAL CARCINOMA; MULTIMODALITY THERAPY; RADIOTHERAPY;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; HUMANS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84887099648     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2013.07.006     Document Type: Review

References (61)

1. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Jemal A., Center M.M., DeSantis C., et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010, 19:1893-1907.
3. Pearson J.G. The present status and future potential of radiotherapy in the management of esophageal cancer. Cancer 1977, 39:882-890.
4. Van Hagen P., Hulshof M.C., van Lanschot J.J., et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012, 366:2074-2084.
5. Gholipour C., Shalchi R.A., Abbasi M. A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis Esophagus 2008, 21:322-327.
6. Tran G.D., Sun X.D., Abnet C.C., et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer 2005, 113:456-463.
7. Pohl H., Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005, 97:142-146.
8. Brown L.M., Devesa S.S., Chow W.H. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008, 100:1184-1187.
9. Rice T.W., Rusch V.W., Ishwaran H., et al. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer 2010, 116:3763-3773.
10. Rice T.W., Rusch V.W., Apperson-Hansen C., et al. Worldwide esophageal cancer collaboration. Dis Esophagus 2009, 22:1-8.
11. Nigro N.D., Vaitkevicius V.K., Considine B. Combined therapy for cancer of the anal canal: a preliminary report. 1974. Dis Colon Rectum 1993, 36:709-711.
12. John M.J., Flam M.S., Mowry P.A., et al. Radiotherapy alone and chemoradiation for nonmetastatic esophageal carcinoma. A critical review of chemoradiation. Cancer 1989, 63:2397-2403.
13. Keane T.J., Harwood A.R., Elhakim T., et al. Radical radiation therapy with 5-fluorouracil infusion and mitomycin C for oesophageal squamous carcinoma. Radiother Oncol 1985, 4:205-210.
14. Herskovic A., Leichman L., Lattin P., et al. Chemo/radiation with and without surgery in the thoracic esophagus: the Wayne State experience. Int J Radiat Oncol Biol Phys 1988, 15:655-662.
15. Araújo C.M., Souhami L., Gil R.A., et al. A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus. Cancer 1991, 67:2258-2261.
16. Smith T.J., Ryan L.M., Douglass H.O., et al. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 1998, 42:269-276.
17. Cooper J.S., Guo M.D., Herskovic A., et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999, 281:1623-1627.
18. Minsky B.D., Pajak T.F., Ginsberg R.J., et al. INT 0123(Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002, 20:1167-1174.
19. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005, 23:2310-2317.
20. Bedenne L., Michel P., Bouché O., et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007, 25:1160-1168.
21. Swisher S.G., Winter K.A., Komaki R.U., et al. A PhaseII study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys 2012, 82:1967-1972.
22. Byfield J.E., Calabro-Jones P., Klisak I., et al. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or ftorafur and X rays. Int J Radiat Oncol Biol Phys 1982, 8:1923-1933.
23. Byfield J.E. 5-Fluorouracil radiation sensitization-a brief review. Invest New Drugs 1989, 7:111-116.
24. Dewit L. Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 1987, 13:403-426.
25. Creane M., Seymour C.B., Colucci S., et al. Radiobiological effects of docetaxel (Taxotere): a potential radiation sensitizer. Int J Radiat Biol 1999, 75:731-737.
26. Steiger Z., Franklin R., Wilson R.F., et al. Complete eradication of squamous cell carcinoma of the esophagus with combined chemotherapy and radiotherapy. Am Surg 1981, 47:95-98.
27. Wong R., Malthaner R. Combined chemotherapy andradiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006, CD002092.
28. Rohatgi P., Swisher S.G., Correa A.M., et al. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 2005, 104:2365-2372.
29. Chirieac L.R., Swisher S.G., Ajani J.A., et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005, 103:1347-1355.
30. Berger A.C., Farma J., Scott W.J., et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005, 23:4330-4337.
31. Donahue J.M., Nichols F.C., Li Z., et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg 2009, 87:392-398. [discussion: 398-9].
32. Swisher S., Moughan J., Komaki R., et al. Final results of RTOG 0246: a phase II study of selective surgical resection for locoregionally advanced esophageal cancer treated with a paclitaxel-based chemoradiation regimen. J Clin Oncol 2012, 30(Suppl 34). [abstract].
33. Downey R.J., Akhurst T., Ilson D., et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003, 21:428-432.
34. Flamen P., Lerut A., Van Cutsem E., et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000, 18:3202-3210.
35. Heeren P.A., Jager P.L., Bongaerts F., et al. Detection of distant metastases in esophageal cancer with (18)F-FDG PET. J Nucl Med 2004, 45:980-987.
36. Kato H., Nakajima M., Sohda M., et al. The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer 2009, 115:3196-3203.
37. Suzuki A., Xiao L., Hayashi Y., et al. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 2011, 117:4823-4833.
38. Rizk N., Downey R.J., Akhurst T., et al. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg 2006, 81:1076-1081.
39. Weber W.A., Ott K., Becker K., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001, 19:3058-3065.
40. Flamen P., Van Cutsem E., Lerut A., et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002, 13:361-368.
41. Skinner H.D., McCurdy M.R., Echeverria A.E., et al. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 2013, 52:1002-1009.
42. Monjazeb A.M., Riedlinger G., Aklilu M., et al. Outcomes of patients with esophageal cancer staged with [18F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?. J Clin Oncol 2010, 28:4714-4721.
43. Vallböhmer D., Hölscher A.H., Dietlein M., et al. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 2009, 250:888-894.
44. Ilson D.H., Minsky B.D., Ku G.Y., et al. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer 2012, 118:2820-2827.
45. Kauppi J.T., Oksala N., Salo J.A., et al. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT. Acta Oncol 2012, 51:636-644.
46. Klaeser B., Nitzsche E., Schuller J.C., et al. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). Onkologie 2009, 32:724-730.
47. Scheer R.V., Fakiris A.J., Johnstone P.A. Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer. Int J Radiat Oncol Biol Phys 2011, 80:996-1001.
48. Ajani J.A., Correa A.M., Hofstetter W.L., et al. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 2012, 23:2638-2642.
49. Cheedella N.K., Suzuki A., Xiao L., et al. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol 2013, 24(5):1262-1266.
50. Andersen A.P., Berdal P., Edsmyr F., et al. Irradiation, chemotherapy and surgery in esophageal cancer: a randomized clinical study. The first Scandinavian trial in esophageal cancer. Radiother Oncol 1984, 2:179-188.
51. Earle J.D., Gelber R.D., Moertel C.G., et al. A controlled evaluation of combined radiation and bleomycin therapy for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 1980, 6:821-826.
52. Kaneta T., Takai Y., Nemoto K., et al. Effects of combination chemoradiotherapy with daily low-dose CDDP for esophageal cancer-results of a randomized trial. Gan To Kagaku Ryoho 1997, 24:2099-2104. [in Japanese].
53. Li A., Su B., Lin Y. 48 Patients with advanced esophageal cancer treated with DDP+5-Fu combined radiotherapy. Chinese Journal Clinical Oncology Rehabilitation 2000, 7(6):79-80.
54. Roussel A., Haegele P., Paillot B. Results of the EORTC-GTCCT Phase III trial of irradiation vs irradiation and CDDP in inoperable esophageal cancer. Proc Annu Meet Am Soc Clin Oncol 1994, 13:199.
55. Slabber C.F., Nel J.S., Schoeman L., et al. A randomized study of radiotherapy alone versus radiotherapy plus 5-fluorouracil and platinum in patients with inoperable, locally advanced squamous cancer of the esophagus. Am J Clin Oncol 1984, 21:462-465.
56. Zhang Z.F. Radiation combined with bleomycin in esophageal carcinoma-a randomized study of 99 patients. Zhonghua Zhong Liu Za Zhi 1984, 6:372-374. [in Chinese].
57. Hatlevoll R., Hagen S., Hansen H.S., et al. Bleomycin/cis-platin as neoadjuvant chemotherapy before radical radiotherapy in localized, inoperable carcinoma of the esophagus. A prospective randomized multicentre study: the second Scandinavian trial in esophageal cancer. Radiother Oncol 1992, 24:114-116.
58. Hishikawa Y., Miura T., Oshitani T., et al. A randomized prospective study of adjuvant chemotherapy after radiotherapy in unresectable esophageal carcinoma. Dis Esophagus 1991, 4(2):85-90.
59. Roussel A., Bleiberg H., Dalesio O., et al. Palliative therapy of inoperable oesophageal carcinoma with radiotherapy and methotrexate: final results of a controlled clinical trial. Int J Radiat Oncol Biol Phys 1989, 16:67-72.
60. Wobbes T., Baron B., Paillot B., et al. Prospective randomised study of split-course radiotherapy versus cisplatin plus split-course radiotherapy in inoperable squamous cell carcinoma of the oesophagus. Eur J Cancer 2001, 37:470-477.
61. Zhou J.C. Randomized trial of combined chemotherapy including high dose cisplatin and radiotherapy for esophageal cancer. Zhonghua Zhong Liu Za Zhi 1991, 13:291-294. [in Chinese].